175 related articles for article (PubMed ID: 17435182)
1. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity.
Gaidukov L; Tawfik DS
J Lipid Res; 2007 Jul; 48(7):1637-46. PubMed ID: 17435182
[TBL] [Abstract][Full Text] [Related]
2. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux.
Gaidukov L; Rosenblat M; Aviram M; Tawfik DS
J Lipid Res; 2006 Nov; 47(11):2492-502. PubMed ID: 16914770
[TBL] [Abstract][Full Text] [Related]
3. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I.
Gaidukov L; Tawfik DS
Biochemistry; 2005 Sep; 44(35):11843-54. PubMed ID: 16128586
[TBL] [Abstract][Full Text] [Related]
4. The effect of HDL-bound and free PON1 on copper-induced LDL oxidation.
Bayrak A; Bayrak T; Bodur E; Kılınç K; Demirpençe E
Chem Biol Interact; 2016 Sep; 257():141-6. PubMed ID: 27510818
[TBL] [Abstract][Full Text] [Related]
5. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.
Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS
Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294
[TBL] [Abstract][Full Text] [Related]
6. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux.
Rosenblat M; Gaidukov L; Khersonsky O; Vaya J; Oren R; Tawfik DS; Aviram M
J Biol Chem; 2006 Mar; 281(11):7657-65. PubMed ID: 16407304
[TBL] [Abstract][Full Text] [Related]
7. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.
Sorenson RC; Bisgaier CL; Aviram M; Hsu C; Billecke S; La Du BN
Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2214-25. PubMed ID: 10479665
[TBL] [Abstract][Full Text] [Related]
8. Bovine paraoxonase 1 activities in serum and distribution in lipoproteins.
Miyamoto T; Takahashi Y; Oohashi T; Sato K; Oikawa S
J Vet Med Sci; 2005 Mar; 67(3):243-8. PubMed ID: 15805725
[TBL] [Abstract][Full Text] [Related]
9. HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress.
Moren X; Deakin S; Liu ML; Taskinen MR; James RW
J Lipid Res; 2008 Jun; 49(6):1246-53. PubMed ID: 18314464
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic functions and clinical importance of circulating HDL-PON1 complex.
Mahrooz A
Adv Clin Chem; 2024; 121():132-171. PubMed ID: 38797541
[TBL] [Abstract][Full Text] [Related]
11. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.
Rosenblat M; Ward S; Volkova N; Hayek T; Aviram M
Biofactors; 2012; 38(4):292-9. PubMed ID: 22674772
[TBL] [Abstract][Full Text] [Related]
12. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups.
Jaouad L; de Guise C; Berrougui H; Cloutier M; Isabelle M; Fulop T; Payette H; Khalil A
Atherosclerosis; 2006 Mar; 185(1):191-200. PubMed ID: 16026789
[TBL] [Abstract][Full Text] [Related]
13. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles.
Mackness M; Mackness B
Gene; 2015 Aug; 567(1):12-21. PubMed ID: 25965560
[TBL] [Abstract][Full Text] [Related]
14. Serum Amyloid A, Paraoxonase-1 Activity, and Apolipoprotein Concentrations as Biomarkers of Subclinical Atherosclerosis Risk in Adrenal Incidentaloma Patients.
Imga NN; Topcuoglu C; Berker D; Turhan T
Arch Med Res; 2018 Apr; 49(3):182-190. PubMed ID: 30031631
[TBL] [Abstract][Full Text] [Related]
15. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo.
Gugliucci A
Clin Chim Acta; 2014 Feb; 429():38-45. PubMed ID: 24280342
[TBL] [Abstract][Full Text] [Related]
16. Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia.
Liu ML; James RW; Ylitalo K; Taskinen MR
Nutr Metab Cardiovasc Dis; 2004 Apr; 14(2):81-7. PubMed ID: 15242240
[TBL] [Abstract][Full Text] [Related]
17. Effects of caloric restriction and gender on rat serum paraoxonase 1 activity.
Thomàs-Moyà E; Gianotti M; Lladó I; Proenza AM
J Nutr Biochem; 2006 Mar; 17(3):197-203. PubMed ID: 16214326
[TBL] [Abstract][Full Text] [Related]
18. In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.
Gaidukov L; Bar D; Yacobson S; Naftali E; Kaufman O; Tabakman R; Tawfik DS; Levy-Nissenbaum E
BMC Clin Pharmacol; 2009 Nov; 9():18. PubMed ID: 19922610
[TBL] [Abstract][Full Text] [Related]
19. Relationship between selected oxidative stress markers and lipid risk factors for cardiovascular disease in middle-aged adults and its possible clinical relevance.
Viktorinova A; Svitekova K; Stecova A; Krizko M
Clin Biochem; 2016 Aug; 49(12):868-72. PubMed ID: 27240017
[TBL] [Abstract][Full Text] [Related]
20. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity.
Rozenberg O; Aviram M
Biochem Biophys Res Commun; 2006 Dec; 351(2):492-8. PubMed ID: 17070779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
